Edwards Lifesciences (EW) Receivables (2009 - 2026)

Edwards Lifesciences has reported Receivables for 18 years, with the latest figure at $973.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 29.41% year-over-year to $973.0 million; the trailing twelve-month figure through Mar 2026 stood at $973.0 million (up 29.41% YoY), and the FY2025 full-year result was $912.1 million, up 520.05% from the prior year.
• Receivables for Q1 2026 stood at $973.0 million, up from $912.1 million in the prior quarter.
• The five-year high for Receivables was $973.0 million in Q1 2026, with the low at $120.1 million in Q3 2024.
• Average Receivables over 5 years is $727.2 million, with a median of $802.1 million recorded in 2023.
• Year-over-year, Receivables plunged 85.03% in 2024 and surged 643.38% in 2025.
• Tracing EW's Receivables over 5 years: stood at $699.1 million in 2022, then climbed by 18.45% to $828.1 million in 2023, then plunged by 82.24% to $147.1 million in 2024, then surged by 520.05% to $912.1 million in 2025, then rose by 6.68% to $973.0 million in 2026.
• The last three Receivables figures came in at $973.0 million (Q1 2026), $912.1 million (Q4 2025), and $892.8 million (Q3 2025), per Business Quant data.

Peer Comparison